A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib

In this study, we delved into the safety profile of alpelisib, an FDA-approved treatment for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, and PIK3CA-Related Overgrowth Spectrum (PROS). Despite its approval, real-world, long-term safety data is lackin...

Full description

Bibliographic Details
Main Authors: Yu Lin, Xinlei Zheng, Yan Chen, Qichun Nian, Li Lin, Maohua Chen
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Heliyon
Subjects:
Alpelisib
Adverse event
FAERS database
Disproportionality analysis
Pharmacovigilance
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024035606

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024035606

Similar Items